Altria Group, Inc. (NYSE:MO) and Philip Morris International Inc. (NYSE:PM) have entered into reciprocal contract manufacturing arrangements designed to improve manufacturing efficiency and expand their operational flexibility. The first shipments are expected in 2027, while both companies said the agreements are not expected to have a material impact on their 2026 results.
The deal is particularly relevant for Altria Group, Inc. (NYSE:MO) because it is looking to increase cigarette imports and exports and capitalize on the U.S. “double duty drawback” system. The tax mechanism allows tobacco companies to recover certain federal excise taxes previously paid on products that are later exported, potentially improving the economics of international tobacco trade.
For Philip Morris International Inc. (NYSE:PM), the agreement provides access to Altria’s manufacturing capabilities while allowing PMI to maintain its existing international-focused cigarette strategy. PMI has emphasized that the arrangement does not mean it plans to sell cigarettes in the U.S.
Jonathan Weiss/Shutterstock.com
Bull and Bear Case for Altria
The biggest positive for Altria Group, Inc. (NYSE:MO) is the potential to generate additional economic value from its existing manufacturing infrastructure. Rather than relying entirely on the declining U.S. cigarette market, Altria can use manufacturing relationships and international trade flows to create additional opportunities.
The double duty drawback could make exports particularly attractive. If Altria can increase qualifying exports while recovering previously paid excise taxes, the company could improve the profitability of its traditional tobacco operations. That would provide another source of cash flow at a time when cigarette volumes in the U.S. continue to face long-term pressure.
The arrangement could also improve manufacturing efficiency. Altria said the deal is intended to enhance operational capabilities and generate economic benefits that can support investment in its broader strategy. For investors, that matters because Altria’s investment case is still heavily tied to its ability to generate strong cash flow from a shrinking cigarette market. Any efficiency gains or additional revenue opportunities could help support earnings, dividends, and investment in newer nicotine products.
The main concern is that investors could overestimate the financial impact of the agreement. Both companies do not expect the arrangement to materially affect 2026 results, and the first shipments are not expected until 2027. More importantly, the deal does not change the fundamental problem facing Altria Group, Inc. (NYSE:MO): cigarette consumption in the U.S. is declining. Manufacturing efficiencies and export opportunities can help offset some of that pressure, but they do not eliminate the structural decline in the traditional cigarette business.
There is also execution risk. The potential benefits depend on Altria successfully expanding qualifying imports and exports and capturing the anticipated tax and manufacturing efficiencies. The company will also need to navigate regulatory requirements and changing tobacco policies in different markets.
So, while the deal is strategically useful, it should not be viewed as a major growth catalyst on its own.
Bull and Bear Case for Philip Morris
The agreement could be more strategically significant for Philip Morris International Inc. (NYSE:PM) because it gives the company additional manufacturing flexibility while it continues to expand its broader nicotine business. PMI has been shifting its portfolio toward smoke-free products, and the company has continued to invest heavily in alternatives to traditional cigarettes. Access to Altria’s manufacturing capabilities could allow PMI to optimize production and supply chains without changing its international commercial strategy.
The arrangement also demonstrates that PMI can benefit from Altria’s U.S. manufacturing footprint without directly entering the U.S. cigarette market. That gives PMI another way to improve operational efficiency while preserving its focus on international markets.
If the arrangement produces meaningful cost savings over time, those savings could strengthen PMI’s already strong cash-generation profile and help fund continued investment in smoke-free products.
The biggest limitation is that the agreement is not a major new revenue stream for Philip Morris International Inc. (NYSE:PM). The companies are essentially using each other’s manufacturing capabilities more efficiently rather than creating an entirely new business. PMI also remains exposed to the long-term decline of traditional cigarettes. While its smoke-free portfolio provides a potential growth engine, combustible tobacco remains an important part of the business.
There is also a risk that investors interpret the manufacturing agreement as more transformational than it really is. Since the initial financial impact is expected to be limited and shipments will not begin until 2027, the near-term earnings benefit could be modest.
Conclusion
The agreement is incrementally positive for both Altria Group, Inc. (NYSE:MO) and Philip Morris International Inc. (NYSE:PM), but the benefits are more strategic than transformational in the near term. For Altria, the deal could be particularly useful because the company can potentially leverage its manufacturing footprint and the double duty drawback to find additional value in its traditional tobacco operations. That could help offset some of the pressure from declining U.S. cigarette volumes.
For PMI, the agreement provides greater manufacturing flexibility and could produce efficiency gains while the company continues its transition toward smoke-free products. Still, investors should keep expectations in check. Neither company expects a material impact on 2026 results, and the first shipments are expected in 2027. The deal therefore does not fundamentally change either company’s investment thesis.
Overall, the agreement strengthens the operational and financial flexibility of both companies, with Altria potentially having more to gain from the tax-related export opportunity. But the longer-term outlook for both stocks will continue to depend much more on cigarette volumes, pricing power, regulatory developments and the growth of reduced-risk nicotine products than on this manufacturing agreement alone.
READ NEXT: Can Walmart’s (WMT) New Scenario Brand Drive Its Next Phase of Growth? and Abbott Pays $670 Million to Settle Formula Claims as Legal Risks Persist
Disclosure: None. This article is originally published at Insider Monkey.
